AbbVie Inc (ABBV)vsArdent Health Partners, Inc. (ARDT)
ABBV
AbbVie Inc
$262.55
-0.20%
HEALTHCARE · Cap: $454.36B
ARDT
Ardent Health Partners, Inc.
$10.72
+0.28%
HEALTHCARE · Cap: $1.57B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 905% more annual revenue ($64.39B vs $6.41B). ABBV leads profitability with a 9.8% profit margin vs 1.2%. ARDT trades at a lower P/E of 19.6x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ARDT
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$262.55
$110.73 premium
Intrinsic value data unavailable for ARDT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
1.2% margin — thin
Operating margin of 3.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ARDT
The strongest argument for ARDT centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 1.68 is elevated, increasing financial risk. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
ARDT carries more volatility with a beta of 0.70 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 40/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc. is a leading healthcare organization based in Nashville, Tennessee, focused on providing high-quality, patient-driven care through an extensive network of hospitals and outpatient facilities. The company emphasizes innovation and operational excellence, offering a comprehensive range of acute care services tailored to the specific needs of the communities it serves. With a solid financial foundation and a strategic growth plan, Ardent is well-prepared to enhance healthcare access and improve patient outcomes in a dynamic healthcare environment.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?